We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of MRA in Patients With Rheumatoid Arthritis (RA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00144651
Recruitment Status : Completed
First Posted : September 5, 2005
Last Update Posted : August 9, 2013
Sponsor:
Information provided by (Responsible Party):
Chugai Pharmaceutical

Brief Summary:
This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: MRA(Tocilizumab) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 135 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Extension, Phase II Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Were Participated in Study MRA009JP
Study Start Date : August 2001
Primary Completion Date : June 2009
Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: MRA(Tocilizumab)
8mg/kg/4 weeks for 1 year



Primary Outcome Measures :
  1. ACR 20% responder rate compared to the pre-treatment in the preceding study [ Time Frame: throughout study ]
  2. Frequency and severity of adverse events and adverse drug reactions [ Time Frame: week0,week4,week8,week12,and LOBS ]

Secondary Outcome Measures :
  1. Time course of DAS28,compared to the pre-treatment in the preceding study [ Time Frame: week 0,week 4,week 8,week 12, LOBS ]
  2. Time course of the ACR 20%, 50%, and 70% responder rates compared to the pre-treatment in the preceding study [ Time Frame: week 0,week 4,week 8,week 12, LOBS ]
  3. ACR N AUC compared to the pre-treatment in the preceding study [ Time Frame: week 0,week 4,week 8,week 12, LOBS ]
  4. Time course of the ACR core set variables compared to the pre-treatment in the preceding study [ Time Frame: week 0,week 4,week 8,week 12, LOBS ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients administered MRA more than 2 times in preceding study, MRA009JP, and evaluated the efficacy and the safety.
  • Patients confirmed to have shown the safety in the preceding study.

Exclusion Criteria:

  • Patients with Class IV Steinbrocker functional activity at evaluation within 4 weeks before treatment with the study drug
  • Patients who received any of the following treatments between the start of preceding study and the registration of this study.

    1. Plasma exchange therapy
    2. Surgical treatment (e.g., operation)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00144651


Sponsors and Collaborators
Chugai Pharmaceutical
Investigators
Study Director: Takahiro Kakehi Chugai Pharmaceutical

Responsible Party: Chugai Pharmaceutical
ClinicalTrials.gov Identifier: NCT00144651     History of Changes
Other Study ID Numbers: MRA010JP
First Posted: September 5, 2005    Key Record Dates
Last Update Posted: August 9, 2013
Last Verified: August 2013

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases